332 related articles for article (PubMed ID: 27322918)
1. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.
Gerbens LA; Prinsen CA; Chalmers JR; Drucker AM; von Kobyletzki LB; Limpens J; Nankervis H; Svensson Å; Terwee CB; Zhang J; Apfelbacher CJ; Spuls PI;
Allergy; 2017 Jan; 72(1):146-163. PubMed ID: 27322918
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
[TBL] [Abstract][Full Text] [Related]
4. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC;
J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560
[TBL] [Abstract][Full Text] [Related]
5. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
6. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL;
JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090
[TBL] [Abstract][Full Text] [Related]
7. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Chalmers JR; Simpson E; Apfelbacher CJ; Thomas KS; von Kobyletzki L; Schmitt J; Singh JA; Svensson Å; Williams HC; Abuabara K; Aoki V; Ardeleanu M; Awici-Rasmussen M; Barbarot S; Berents TL; Block J; Bragg A; Burton T; Bjerring Clemmensen KK; Creswell-Melville A; Dinesen M; Drucker A; Eckert L; Flohr C; Garg M; Gerbens LA; Graff AL; Hanifin J; Heinl D; Humphreys R; Ishii HA; Kataoka Y; Leshem YA; Marquort B; Massuel MA; Merhand S; Mizutani H; Murota H; Murrell DF; Nakahara T; Nasr I; Nograles K; Ohya Y; Osterloh I; Pander J; Prinsen C; Purkins L; Ridd M; Sach T; Schuttelaar ML; Shindo S; Smirnova J; Sulzer A; Synnøve Gjerde E; Takaoka R; Vestby Talmo H; Tauber M; Torchet F; Volke A; Wahlgren CF; Weidinger S; Weisshaar E; Wollenberg A; Yamaga K; Zhao CY; Spuls PI
Br J Dermatol; 2016 Jul; 175(1):69-79. PubMed ID: 27436240
[TBL] [Abstract][Full Text] [Related]
8. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.
Spuls PI; Gerbens LAA; Simpson E; Apfelbacher CJ; Chalmers JR; Thomas KS; Prinsen CAC; von Kobyletzki LB; Singh JA; Williams HC; Schmitt J;
Br J Dermatol; 2017 Apr; 176(4):979-984. PubMed ID: 27858989
[TBL] [Abstract][Full Text] [Related]
9. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Furue M; Gerbens LAA; Prinsen CAC; Schmitt J; Spuls PI; Thomas KS; Williams HC; Simpson EL;
J Am Acad Dermatol; 2020 May; 82(5):1181-1186. PubMed ID: 31926221
[TBL] [Abstract][Full Text] [Related]
10. What are the best outcome measurements for atopic eczema? A systematic review.
Schmitt J; Langan S; Williams HC;
J Allergy Clin Immunol; 2007 Dec; 120(6):1389-98. PubMed ID: 17910890
[TBL] [Abstract][Full Text] [Related]
11. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review.
Gerbens LA; Chalmers JR; Rogers NK; Nankervis H; Spuls PI;
Br J Dermatol; 2016 Oct; 175(4):678-86. PubMed ID: 27012805
[TBL] [Abstract][Full Text] [Related]
12. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
[TBL] [Abstract][Full Text] [Related]
13. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2020 Nov; ():. PubMed ID: 33179283
[TBL] [Abstract][Full Text] [Related]
14. Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.
Jacobson ME; Thomas KS; Apfelbacher CJ; Leshem YA; Williams HC; Gerbens LAA; Spuls PI; Schmitt J; Howells L; Katoh N; Simpson EL;
Arch Dermatol Res; 2023 Nov; 315(9):2617-2622. PubMed ID: 37432466
[TBL] [Abstract][Full Text] [Related]
15. The HOME Core outcome set for clinical trials of atopic dermatitis.
Williams HC; Schmitt J; Thomas KS; Spuls PI; Simpson EL; Apfelbacher CJ; Chalmers JR; Furue M; Katoh N; Gerbens LAA; Leshem YA; Howells L; Singh JA; Boers M;
J Allergy Clin Immunol; 2022 Jun; 149(6):1899-1911. PubMed ID: 35351441
[TBL] [Abstract][Full Text] [Related]
16. Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review.
Heinl D; Prinsen CAC; Sach T; Drucker AM; Ofenloch R; Flohr C; Apfelbacher C
Br J Dermatol; 2017 Apr; 176(4):878-889. PubMed ID: 27543747
[TBL] [Abstract][Full Text] [Related]
17. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries.
Vermeulen FM; Gerbens LAA; Bosma AL; Apfelbacher CJ; Irvine AD; Arents BWM; Barbarot S; Deleuran M; Eichenfield LF; Manca A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Middelkamp-Hup MA; Spuls PI; Flohr C;
Br J Dermatol; 2019 Sep; 181(3):492-504. PubMed ID: 30719709
[TBL] [Abstract][Full Text] [Related]
18. Measurement properties of patient-reported outcome measures for eczema control: a systematic review.
Stuart BL; Howells L; Pattinson RL; Chalmers JR; Grindlay D; Rogers NK; Grinich E; Pawlitschek T; Simpson EL; Thomas KS
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):1987-1993. PubMed ID: 33977561
[TBL] [Abstract][Full Text] [Related]
19. What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment.
Lloyd-Lavery A; Solman L; Grindlay DJC; Rogers NK; Thomas KS; Harman KE
Clin Exp Dermatol; 2019 Jun; 44(4):376-380. PubMed ID: 30706507
[TBL] [Abstract][Full Text] [Related]
20. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review.
Heinl D; Prinsen CA; Deckert S; Chalmers JR; Drucker AM; Ofenloch R; Humphreys R; Sach T; Chamlin SL; Schmitt J; Apfelbacher C
Allergy; 2016 Mar; 71(3):358-70. PubMed ID: 26564008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
